Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT06613750

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06613750
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06613750. Randomized; no masking; primary purpose treatment. Start 2024-06-01 (actual); primary completion 2024-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
Acronym
SG Metformin
Condition
Type 2 Diabetes Mellitus
Condition
Glucotoxicity
Intervention (Drug)
Sitagliptin and Gliclazide
Intervention (Drug)
Metformin
Lead sponsor
Zhibin Xu (class: other)
Collaborator
Nanfang Hospital, Southern Medical University (class: other)

Record details

Record id
cardio:ct-nct06613750
Content hash
da37182768f8c1cd133228e1daa05984c1bf2e4b7913164fad6d22a04a9d2c0a